|
|
|
|
|
AGL CLO Ltd., Series 2021-12A, Class B, (3-mo. CME
Term SOFR + 1.86%), 7.14%, 07/20/34(a)(b)
|
|
|
|
AIMCO CLO Ltd., Series 2020-11A, Class CR2, (3-mo.
CME Term SOFR + 1.90%), 7.14%, 07/17/37(a)(b)
|
|
|
|
Anchorage Capital CLO Ltd., Series 2019-11A,
Class C1R2, (3-mo. CME Term SOFR + 2.40%),
7.74%, 07/22/37(a)(b)
|
|
|
|
Bain Capital Credit CLO Ltd.(a)(b)
|
|
|
|
Series 2021-4A, Class B, (3-mo. CME Term SOFR +
1.91%), 7.19%, 10/20/34
|
|
|
|
Series 2021-6A, Class B, (3-mo. CME Term SOFR +
1.91%), 7.19%, 10/21/34
|
|
|
|
|
|
|
|
Series 2019-2A, Class BRR, (3-mo. CME Term SOFR
+ 2.40%), 7.53%, 02/20/36
|
|
|
|
Series 2021-1A, Class B, (3-mo. CME Term SOFR +
2.31%), 7.61%, 04/15/34
|
|
|
|
Series 2024-22A, Class B, (3-mo. CME Term SOFR +
2.35%), 7.67%, 04/15/37
|
|
|
|
Battalion CLO X Ltd., Series 2016-10A, Class BR2, (3-
mo. CME Term SOFR + 2.31%), 7.59%, 01/25/35(a)(b)
|
|
|
|
Birch Grove CLO Ltd., Series 2024-9A, Class A1, (3-mo.
CME Term SOFR + 1.40%), 6.58%, 10/22/37(a)(b)
|
|
|
|
Bryant Park Funding Ltd., Series 2024-22A, Class C,
(3-mo. CME Term SOFR + 2.60%), 7.91%,
04/15/37(a)(b)
|
|
|
|
Canyon CLO Ltd., Series 2021-3A, Class B, (3-mo. CME
Term SOFR + 1.96%), 7.26%, 07/15/34(a)(b)
|
|
|
|
CarVal CLO II Ltd., Series 2019-1A, Class DR, (3-mo.
CME Term SOFR + 3.46%), 8.74%, 04/20/32(a)(b)
|
|
|
|
CarVal CLO IV Ltd., Series 2021-1A, Class D, (3-mo.
CME Term SOFR + 3.51%), 8.79%, 07/20/34(a)(b)
|
|
|
|
CarVal CLO VC Ltd., Series 2021-2A, Class C, (3-mo.
CME Term SOFR + 2.46%), 7.76%, 10/15/34(a)(b)
|
|
|
|
|
|
|
|
Series 2015-1A, Class CRR, (3-mo. CME Term SOFR
+ 2.16%), 7.44%, 01/22/31
|
|
|
|
Series 2019-1A, Class CR, (3-mo. CME Term SOFR +
2.31%), 7.59%, 04/20/32
|
|
|
|
Series 2019-5A, Class A2RS, (3-mo. CME Term
SOFR + 2.01%), 7.31%, 01/15/35
|
|
|
|
Cook Park CLO Ltd., Series 2018-1A, Class C, (3-mo.
CME Term SOFR + 2.01%), 7.30%, 04/17/30(a)(b)
|
|
|
|
Elmwood CLO 21 Ltd., Series 2022-8A, Class AR, (3-
mo. CME Term SOFR + 1.65%), 6.93%, 10/20/36(a)(b)
|
|
|
|
Elmwood CLO 26 Ltd, Series 2026-1A, Class C, (3-mo.
CME Term SOFR + 2.40%), 7.69%, 04/18/37(a)(b)
|
|
|
|
Galaxy XXIV CLO Ltd., Series 2024-R, Class CR, (3-mo.
CME Term SOFR + 2.45%), 7.75%, 04/15/37(a)(b)
|
|
|
|
Generate CLO Ltd., Series 7A, Class A1R, (3-mo. CME
Term SOFR + 1.62%), 6.90%, 04/22/37(a)(b)
|
|
|
|
Golub Capital Partners LP, Series 2020-48A, Class C,
(3-mo. CME Term SOFR + 3.06%), 8.35%,
04/17/33(a)(b)
|
|
|
|
Greywolf CLO V Ltd., Series 2015-1A, Class CR, (3-mo.
CME Term SOFR + 3.26%), 8.55%, 01/27/31(a)(b)
|
|
|
|
HalseyPoint CLO Ltd., Series 2021-4A, Class C, (3-mo.
CME Term SOFR + 2.41%), 7.69%, 04/20/34(a)(b)
|
|
|
|